TY - JOUR
T1 - Antiarrhythmic efficacy of ethmozine® (moricizine HCl) compared with disopyramide and propranolol
AU - Pratt, Craig
AU - Butman, Samuel M.
AU - Young, James B.
AU - Knoll, Margaret
AU - English, La Dean
N1 - Funding Information:
From the Baylor College of Medicine, Houston, Texas, and Long Branch Veterans Administration Medical Center, University of California, Irvine, California. This study was supported in part by research grants from Du Pont Pharmaceuticals. Computational assistance provided by the CLINFO project, funded by grant RR-00350, Division of Research Resources, National Institutes of Health, Bethesda, Maryland. Address for reprints: Craig M. Pratt, MD, Section of Cardiology, The Methodist Hospital, 6535 Fannin, MS F-1001, Houston, Texas 77030.
Copyright:
Copyright 2014 Elsevier B.V., All rights reserved.
PY - 1987/10/16
Y1 - 1987/10/16
N2 - In the investigation of new antiarrhythmic drugs, comparative trials with clinically available antiarrhythmic agents provide a perspective from which to judge the new investigational agent. Two clinical investigations of moricizine HCl, each using a placebo-controlled, double-blind, crossover design, are summarized. In the first study, 18 patients with ≥ 30 ventricular premature complexes (VPCs) per hour (mean 369 ± 95) were given propranolol (120 mg daily) compared with moricizine HCl (816 ± 103 mg daily). Propranolol suppressed 38% of VPCs in the study group, moricizine HCl, 81% of VPCs, and the combination of both drugs, 87%. Moricizine HCl was more effective than propranolol in suppressing VPCs at all individual levels > 70% (p < 0.05, McNemar's test). The combination of moricizine HCl and propranolol was well tolerated. The second investigation used a placebo-controlled, double-blind, crossover design to compare the efficacy of disopyramide (600 mg daily) and moricizine HCl (800 mg daily) in 27 patients. Patients had ≥ 40 VPCs/hr on a 24-hour ambulatory electrocardiogram. During moricizine HCl administration, the mean VPC frequency decreased from 524 to 151 VPCs/hr (71.2% reduction). In contrast, disopyramide reduced VPC frequency from 535 to 253 VPCs/hr (52.8% reduction) and demonstrated significantly greater side effects (p < 0.05). Moricizine HCl was more effective than disopyramide in suppressing VPCs at all individual percent reduction levels >70% (p < 0.05, McNemar's test). Moricizine HCl was more effective in suppressing VPCs than either disopyramide or propranolol, with significantly fewer side effects.
AB - In the investigation of new antiarrhythmic drugs, comparative trials with clinically available antiarrhythmic agents provide a perspective from which to judge the new investigational agent. Two clinical investigations of moricizine HCl, each using a placebo-controlled, double-blind, crossover design, are summarized. In the first study, 18 patients with ≥ 30 ventricular premature complexes (VPCs) per hour (mean 369 ± 95) were given propranolol (120 mg daily) compared with moricizine HCl (816 ± 103 mg daily). Propranolol suppressed 38% of VPCs in the study group, moricizine HCl, 81% of VPCs, and the combination of both drugs, 87%. Moricizine HCl was more effective than propranolol in suppressing VPCs at all individual levels > 70% (p < 0.05, McNemar's test). The combination of moricizine HCl and propranolol was well tolerated. The second investigation used a placebo-controlled, double-blind, crossover design to compare the efficacy of disopyramide (600 mg daily) and moricizine HCl (800 mg daily) in 27 patients. Patients had ≥ 40 VPCs/hr on a 24-hour ambulatory electrocardiogram. During moricizine HCl administration, the mean VPC frequency decreased from 524 to 151 VPCs/hr (71.2% reduction). In contrast, disopyramide reduced VPC frequency from 535 to 253 VPCs/hr (52.8% reduction) and demonstrated significantly greater side effects (p < 0.05). Moricizine HCl was more effective than disopyramide in suppressing VPCs at all individual percent reduction levels >70% (p < 0.05, McNemar's test). Moricizine HCl was more effective in suppressing VPCs than either disopyramide or propranolol, with significantly fewer side effects.
UR - http://www.scopus.com/inward/record.url?scp=0023634697&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0023634697&partnerID=8YFLogxK
U2 - 10.1016/0002-9149(87)90722-3
DO - 10.1016/0002-9149(87)90722-3
M3 - Article
C2 - 3310586
AN - SCOPUS:0023634697
SN - 0002-9149
VL - 60
SP - 52
EP - 58
JO - The American Journal of Cardiology
JF - The American Journal of Cardiology
IS - 11
ER -